Author reiterates a bullish view on Fractyl Health ($GUTS), citing its Revita GLP-1 discontinuation opportunity and multiple 2026 catalysts.
GUTS — LONG Author is long-biased on Fractyl Health ($GUTS), a biotech whose Revita one-off procedure may let patients stopping GLP-1s such as Mounjaro or Wegovy maintain weight loss. The mechanism is a large obesity/weight-loss market and a simple procedure that could appeal to patients, practitioners, insurers and regulators, especially after an Oxford study cited by the author said stopping GLP-1s leads to weight regain. Catalysts include 6-month randomized data at the end of January and seven back-to-back 2026 events culminating in an FDA premarket approval filing; the author also notes cash runway into early 2027 and a new CFO hire.
in a nutshell, $GUTS offer an one-off simple procedure which potentially allows people that stop GLP-1s (e.g., Mounjaro, Wegovy) maintain their weight.
This Reddit post, published January 08, 2026, features u/fousekis7 discussing GUTS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/fousekis7 · Tickers: GUTS